Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) announced inducement grants of restricted stock units to new employees under its 2023 Employment Inducement Incentive Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The company granted RSUs for 143,898 shares to 267 new non-executive employees, vesting in three equal annual installments.
Guardant Health (Nasdaq: GH) reported Q1 2026 revenue of $301.7M, up 48% year-over-year, driven by Oncology, Biopharma & Data, and Shield screening. The company raised 2026 revenue guidance to $1.30–$1.32B and expects Shield volume of 230k–245k tests.
Q1 non-GAAP gross margin was 66%, operating expenses rose, net loss was $112.1M, and cash and equivalents were $1.2B as of March 31, 2026.
Guardant Health (Nasdaq: GH) announced FDA approval of Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) on May 4, 2026. The blood-based liquid biopsy detects ESR1 mutations in ER+/HER2- advanced or metastatic breast cancer after prior endocrine therapy.
The approval enables a non-invasive method to identify patients eligible for VEPPANU, marks Guardant's third ESR1 companion diagnostic, and is the platform's 26th companion diagnostic indication with coverage for >300 million lives.
Guardant Health (Nasdaq: GH) announced a multi-year global collaboration with Nuvalent (Nasdaq: NUVL) to use Guardant’s tissue and liquid biopsy portfolio, including the Guardant Infinity™ platform, to support Nuvalent clinical studies and evaluate companion diagnostic (CDx) development and potential joint commercialization.
The partnership will: use Guardant tissue and liquid tests in certain Nuvalent global trials; assess Guardant assays as potential CDx for Nuvalent investigational candidates; and collaborate on global commercialization of Nuvalent therapies and Guardant CDx if approvals occur.
Guardant Health (Nasdaq: GH) will participate in three investor conferences in May–June 2026, including fireside chats and a presentation.
Events: BofA Securities Healthcare Conference (May 12, 10:40 a.m. PT), William Blair Growth Stock Conference (June 2, 9:20 a.m. CT), and Jefferies Global Healthcare Conference (June 3, 11:05 a.m. ET). Live and archived webcasts will be available on the company website.
Guardant Health (Nasdaq: GH) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Live audio will be available on the company’s Investors webpage and archived for replay after the event.
Guardant Health (Nasdaq: GH) said real-world evidence from its InfinityAI platform supported Japan approval of ENHERTU (trastuzumab deruxtecan) for previously treated HER2-positive advanced or recurrent solid tumors.
The MHLW approval was supported by clinical trial data plus supplemental RWE from InfinityAI and Guardant360, supplied in collaboration with Daiichi Sankyo.
Verana Health and Guardant Health (Nasdaq: GH) announced a March 24, 2026 partnership to combine Verana's curated, therapeutic-specific EHR datasets with Guardant's clinicogenomic testing data to accelerate oncology drug development and improve real-world treatment insights.
The merged Verana/COTA portfolio expands reach to >95 million patients, >20,000 clinicians, and accessible oncology patients to over 10 million.
Guardant Health (Nasdaq: GH) will present 28 abstracts, including 3 oral sessions, at AACR Annual Meeting, April 17-22, 2026 in San Diego. Key data include ~92% tissue-of-origin accuracy across >6,000 samples and expanded liquid biopsy actionability of 85% (metastatic breast) and 89% (advanced colorectal).
Presentations highlight methylation-based tumor typing, Guardant360 Liquid epigenomic features, Guardant Reveal MRD use to detect new primary cancers, and a tissue GIS for DNA repair deficiency to inform PARP inhibitor eligibility.
Guardant Health (Nasdaq: GH) launched its Shield™ multi-cancer detection (MCD) laboratory-developed blood test in Asia via a partnership with Manulife, with availability in Hong Kong, Singapore and the Philippines beginning April 2026 for eligible Manulife customers.
The methylation-based Shield MCD screens for 10 cancer types in individuals aged 45+ at typical average risk and has received FDA Breakthrough Device Designation in the United States based on NCI Vanguard study performance.